[1]
K. Byrd and P. Truong, “Bortezomib in the Treatment of Acquired von Willebrand Disease Secondary to Monoclonal Gammopathy of Undetermined Significance”, kjm, vol. 7, no. 4, pp. 167–170, Nov. 2014, doi: 10.17161/kjm.v7i4.11507.